Sm_ninjaWe have been working on liposomes and lipidic nanoparticles for drug/gene delivery. Current activities are focused in the development of non-viral vectors for pDNA/siRNA therapy and receptor-mediated drug targeting.

 

Research Projects

To enhance de-assembly of nanoparticle in acidic endosomes, the core of the nanoparticle has been replaced with calcium phosphate nano-precipitates. The resulting nanoparticles, referred to as LCP, are about forty-fold more effective in delivering siRNA than LPD nanoparticles.
The newest version, LCP-II, is small (about 30-35 nm) and contains a hollow calcium phosphate core.

2[23]

1[37]

 

Publications

  • Li, J., Yang, Y. and Huang, L. Calcium Phosphate Nanoparticles with an Asymmetric Lipid Bilayer Coating for siRNA Delivery to The Tumor. J. Controlled Release 158: 108-114, 2012.
  • Yang, Y., Li, J., Liu, F. and Huang, L. Systemic Delivery of siRNA via LCP Nanoparticle Efficiently Inhibits Lung Metastasis. Molecular Therapy, 20:609-615, 2012.
  • Satterlee, A.B., Yuan, H. and Huang, L. A Radio-Theranostic Nanoparticle with High Specific Drug Loading for Cancer Therapy and Imaging. Journal of Controlled Release, 217:170-182, 2015.

We have developed novel lipid bilayer enclosed nano-precipitate of cisplatin with greater than 80 percent drug loading. The nanoparticles efficiently deliver large amounts of cisplatin to tumor cells in vivo and showed a significant bystander effect. Cisplatin diffuses from the cells taken up the nanoparticles and kills the neighboring cells. Cisplatin NPs and Gemcitabine NPs can be co-encapsulated in the same PLGA NPs for precise ratio-metric delivery of two drugs for treating bladder cancer.

 


 

5[12]

 


Publications

  • Guo, S. T., Wang, Y. H., Miao, L., Xu, Z. H., Lin, C. M., Zhang, Y. and Huang, L. Lipid-Coated Cisplatin Nanoparticles Induce Neighboring Effect and Exhibit Enhanced Anticancer Efficacy. ACS Nano, 7: 9896-9904, 2013.
  • Guo, S. T., Miao, L., Wang, Y.H. and Huang, L. Unmodified Drug Used as a Material to Construct Nanoparticles: Delivery of Cisplatin for Enhanced Anti-Cancer Therapy. J. Controlled Release, 174:137-142, 2014.
  • Miao, L., Guo, S.T., Zhang, J., Kim, W.Y. and Huang, L. Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer. Advanced Functional Materials, 24(42):6601-6611, 2014.

The tumor microenvironment (TME) serves as a multidrug resistant center for tumors under the assault of chemotherapy and a physiological barrier against the penetration of therapeutic nanoparticles (NP). Tumor associated fibroblasts (TAFs), the major cellular component of TME, are recruited by tumor cells to build the TME, which separates tumor vessels and tumor cells. We have originally discovered that combined NP containing gemcitabine and cisplatin efficiently kill TAFs and down-regulate TME, resulting in excellent inhibition of tumor growth.

6[12]

 

However, a drug resistant phenotype gradually arises after repeated doses of chemotherapeutic NP. In a later study, the acquisition of drug resistant phenotypes in the TME after repeated cisplatin NP treatment was examined. Particularly, this study was aimed at investigating the effects of NP damaged TAFs on neighboring cells and alteration of stromal structure after cisplatin treatment. Findings suggested that while off-targeted NP damaged TAFs and inhibited tumor growth after an initial dose, chronic exposure to cisplatin NP led to elevated secretion of Wnt16 in a paracrine manner in TAFs. Wnt16 upregulation was then attributed to heightened tumor cell resistance and stroma reconstruction. Results attest to the efficacy of Wnt16 knockdown using a nanoparticle delivered siRNA against Wnt16 in damaged TAFs as a promising combinatory strategy to improve efficacy of cisplatin NP in a stroma-rich bladder cancer model.

 

Publications

  • Zhang, J., Miao, L., Guo, S. T., Zhang, Y., Zhang, L., Satterlee, A., Kim, W. Y., and Huang, L. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J. Controlled Release, 182:90-96, 2014.
  • Miao, L., Wang, Y., Lin, C., Xiong, Y., Chen, N., Zhang, Lu., Kim, W., and Huang, L. Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. J. Controlled Release, 217:27-41, 2015.

Using the LCP nanoparticles, we have developed a novel cancer vaccine by encapsulating a peptide of a tumor associated antigen or its mRNA. Subcutaneous administration of the vaccine nanoparticles delivers the antigen to the dendritic cells in the draining lymph nodes and stimulates a strong cytotoxic T-lymphocyte response, leading to inhibition of tumor growth. Vaccine activity can be further enhanced by delivering siRNA against key cytokines, such as TGF-β, that control the suppressive tumor microenvironment. We are currently investigating siRNA, miRNA and/or small molecule drugs that can inhibit the myelo-derived suppressive cells and Treg cells to further enhance the vaccine activity. For example, sunitinib base encapsulated in PLGA NPs can normalize the tumor vasculature and greatly enhance the penetration of polymeric micelles.

Publications

  • Xu, Z.H., Ramishetti S., Tseng, Y.-C., Guo S. T., Wang Y.H., and Huang, L. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J. Controlled Release. 172:259-265, 2013.
  • Xu, Z.H., Wang, Y.H., Zhang, L. and Huang, L. Nanoparticle-Delivered TGF-β siRNA Enhances Vaccination against Advanced Melanoma by Modifying Tumor Microenvironment. ACS Nano, 8(4):3636-3645, 2014.
  • Zhao, Y. Huo, M., Xu, Z. Wang, Y. and Huang, L. Nanoparticle Delivery of CDDO-Me Remodels the Tumor Microenvironment and Enhances Vaccine Therapy for Melanoma. Biomaterials, 68:54-66, 2015.

Huang6.1LCP-II nanoparticles targeted with galactose have been prepared to deliver plasmid DNA to hepatocytes in the liver. Approximately 50 percent of the IV injected nanoparticles accumulate in the liver hepatocytes, with virtually no accumulation in the Kupffer cells.

Through the use of a cationic peptide plasmid DNA is condensed and the delivered DNA was imported to the nuclei of the hepatocytes. Consequently, high levels of transgene expression in the liver were observed. This nonhydrodynamic method of in vivo gene transfer shows a high potential for liver gene therapy.

Publications

  • Hu, Y. X., Haynes, M.T., Wang, Y. H., Liu, F. and Huang, L. A Highly Efficient Synthetic Vector: Non-Hydrodynamic Delivery of DNA to Hepatocyte Nuclei In Vivo. ACS Nano. 7:5376-5384, 2013.
  • Liu, Y., Hu, Y. X. and Huang, L. Influence of Polyethylene Glycol Density and Surface Lipid on Pharmacokinetics and Biodistribution of LCP Nanoparticles. Biomaterials, 35:3027-3034, 2014.

Using LCP nanoparticles, we are able to condense and encapsulate mRNA vaccines, disrupt endosomes for mRNA release, and potentiate dendritic cell maturation for potent immune response. The simultaneous LCP delivery of mRNA vaccine and siRNA against PD-L1 to DCs would further remove the negative regulator during the T cell priming process, lead to increased T cell activation and proliferation.

Publications:

  • Li J, Yang Y, & Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. Journal of controlled release: official journal of the Controlled Release Society. 158(1):108-114, 2012.

11[12]

Metformin a widely implemented anti-diabetic regimen exhibits potent anticancer efficacies. Herein, a polymeric construction of Metformin, PolyMetformin (PolyMet) has been successfully synthesized through conjugation of linear polyethylenimine (PEI) with dicyandiamide. The delocalization of cationic charges in the biguanide groups of PolyMet reduces the toxicity of PEI both in vitro and in vivo. Furthermore, the polycationic properties of PolyMet permits capture of siRNA into a core-membrane structured Lipid-Polycation-Hyaluronic acid (LPH) nanoparticle for systemic gene delivery. Advances herein permit LPH-PolyMet nanoparticles to facilitate siRNA delivery for gene knockdown in xenografts, leading to enhanced tumor suppressive efficacy. Even in the absence of RNAi, LPH-PolyMet nanoparticles acts similarly to Metformin and induces antitumor efficacy through activation of the AMPK and inhibition of the mTOR. In essence, LPH-PolyMet successfully combines the intrinsic anticancer efficacy of Metformin with the tumor suppressive effects of siRNA to enhance therapeutic index of an anticancer gene therapy.

Leaf Huang, PhD

  • Birthdate: September 23, 1946
  • Birthplace: China
  • Citizenship: Naturalized citizen of the United States
  • Phone: 919-843-0736
  • Fax: 919-966-0197
  • E-mail: leafh@unc.edu

Address
UNC Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
CB# 7360
Chapel Hill, NC 27599

Click here for a list of publications

Education

Degree Year University Major
BS 1968 National Taiwan University, Taipei Physics
PhD 1974 Michigan State University, East Lansing, MI Biophysics
Postdoctoral Fellowship 1974-1976 Carnegie Institute of Washington, Baltimore, MD

I was born into a college professor’s family in Taiwan. My father was a professor of horticulture for many years. When I was a teenager, I started working in his lab measuring sugar and protein content of Lichee fruit (it was delicious!).

My official science career started when I was a physics major at the National Taiwan University. In my junior year, I became immensely interested in biology. My professor, however, would not allow me to change to a biology major. I suffered through my senior year and decided to pursue my graduate study in biology, after the completion of a year of military service.

No US graduate program in biology would accept me because of my poor background in biology and chemistry. Only the biophysics program at Michigan State University had enough mercy and courage to take me as a graduate student. I still remember having to learn the difference between a microtubule and a microfilament in a freshman biology class. (I was the only graduate student in the class).

My first lab experience was with Professor Barney Rosenberg who had just discovered cis-platinum as a potent anticancer drug. I really did not have enough wisdom and intelligence to appreciate the work and I chose to work with another professor who played with electron spin resonance. Somehow, those electrons jumping between two giant magnets were much more friendly to me than those mice running around the cage.

I finished my PhD in 1974 and took a postdoc position in Dr. Richard Pagano’s lab at Carnegie Institute of Washington. It took me and my newly-wed wife, Shilling, some time to get used to the life in a big city, i.e. Baltimore. Richard taught me the art and science of liposomes, which became my first love in science.

I went down to Knoxville, TN in 1976 to take on a position as an assistant professor of biochemistry at the University of Tennessee. As soon as we arrived, Shilling and I got lost in Knoxville and decided to ask for directions in a local gas station. A very nice man spent five minutes trying to tell me where the University was, but I could not understand him because of his heavy southern accent. I remember telling my wife, “Let us stay for a couple of years and then move back to the north.”

Well, that couple of years turned into fifteen. We fell in love with the city (picked up our own southern accents!). Our children grew up in Knoxville, and were very reluctant to leave when we decided to move to Pittsburgh in 1991.

We liked Pittsburgh a lot except for the occasional harsh winters. Shilling and I finally became used to our empty nest, as both of our children have left home for college. I liked my job at Pitt, which gave me a chance to direct a new Center for Pharmacogenetics. I also hoped that Professor Rosenberg would not notice the fact that I have started working with cis-platinum.

Well, the time came again for another move; this time, going back to the South. Our lab (the Laboratory of Drug Targeting) moved with me to the University of North Carolina at Chapel Hill in July of 2005. I am now an Eshelman Distinguished Professor at the UNC Eshelman School of Pharmacy.

God Bless You!!

Leaf Huang

University of North Carolina at Chapel Hill

2005-pres. Division of Molecular Pharmaceutics
UNC Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, NC
Fred Eshelman Distinguished Professor and Chair

University of Pittsburgh

1999-2005 Department of Pharmaceutical Sciences
School of Pharmacy University of Pittsburgh
Pittsburgh, PA

The Joseph Koslow Professor of
Pharmaceutical Sciences
1999-1999 School of Pharmacy
University of Pittsburgh
Pittsburgh, PA
Associate Dean for Research
1999-2005 Center for Pharmacogenetics School of Pharmacy
University of Pittsburgh
Pittsburgh, PA
Director
2001-2005 Department of Bioengineering
School of Engineering
University of Pittsburgh
Pittsburgh, PA
Professor
(Secondary Appointment)
1999-2005 Department of Pharmacology
School of Medicine
University of Pittsburgh
Pittsburgh, PA
Professor
(Secondary Appointment)
1997-1999 Molecular Pharmacology Training Program
Interdiscipline Biomedical Graduate Program
School of Medicine University of Pittsburgh
Pittsburgh, PA
Director
1993-2005 Liposome Vector Core
Pittsburgh Center for Human Gene Therapy
University of Pittsburgh
Pittsburgh, PA
Director
1992-1999 Department of Pharmaceutical Sciences
School of Pharmacy
University of Pittsburgh
Pittsburgh, PA
Professor
(Joint Appointment)
1992 Pittsburgh Cancer Institute
Pittsburgh, PA
Full Member
1991-1999 Department of Pharmacology
University of Pittsburgh School of Medicine
Pittsburgh, PA
Professor with tenure
Head of Laboratory
of Drug Targeting
1991 Department of Molecular Genetics and Biochemistry
University of Pittsburgh School of Medicine
Pittsburgh, PA
Professor
(Secondary Appointment)

University of Tennessee

1985-1991 Department of Biochemistry
University of Tennessee
Knoxville, TN
Professor with tenure
1978-1991 University of Tennessee Cell, Molecular and
Developmental Biology Program
University of Tennessee
Knoxville, TN
Faculty Member
1987-1991 Comparative and Experimental Medicine Program
University of Tennessee
Knoxville, TN
Faculty Member
1985-1991 Biotechnology Program
University of Tennessee
Knoxville, TN
Faculty Member
1985-1986 Cell, Molecular and Developmental Biology Program
University of Tennessee
Knoxville, TN
Acting Director
1980-1985 Department of Biochemistry
University of Tennessee
Knoxville, TN
Associate Professor
with tenure
1982-1985 Department of Biochemistry
University of Tennessee
Knoxville, TN
Associate Head
1976-1980 Department of Biochemistry
University of Tennessee
Knoxville, TN
Assistant Professor

Carnegie Institution

1974-1976 Department of Embryology
Carnegie Institution of Washington
Baltimore, MD
Postdoctoral Fellow

Other Appointments

2010 Chung-Yuan Christian University, Taiwan Visiting Chair Professor
2009 Sichuan University, Chengdu, China Honorary Professor
1987-1988 Research and Development
LipoGen, Inc.
Vice President
1986 Department of Biology
Lanzhou University
Lanzhou, China
Visiting Professor
(Honorary Appointment)
1985 Department of Biological
Sciences and Biotechnology
Tsinghua University
Beijing, China
Visiting Professor
(Honorary Appointment)
Summer
1983
Institute of Zoology
Academia Sinica
Beijing, China
Research Scholar
Summer
1982
Department of Chemistry
Stanford University
Visiting Research
Scholar
1980 Department of Biology
Beijing University
Beijing, China
Visiting Professor
(Honorary Appointment)
2013-2016 Fudan University, China Advanced Visiting Scholar
2012 Fourth Military Medical University, China Visiting Professor
2012-present Division of Molecular Pharmaceutics
Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, NC
Fred Eshelman Distinguished
Professor
(with tenure)
2010-present UNC-NCSU Joint Department of Biomedical Engineering
University of North Carolina at Chapel Hill
Chapel Hill, NC
Professor (joint appointment)
2009 Sichuan University, Chengdu, China Honorary Professor
2005-2012, 2015-present Division of Molecular Pharmaceutics
Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, NC
Fred Eshelman Distinguished
Professor
(with tenure) and Chair

Honors and Awards

1970-1971 Matthey-Bishop Predoctoral Fellowship
1974-1975 Carnegie Institution of Washington Fellowship
1975-1976 U.S. Public Health Service Research Fellowship
1983 Chancellor’s Research Scholar, University of Tennessee, Knoxville
1981-1986 Research Career Development Award, NIH
1984-1991 Member, Science Alliance Center of Excellence University of Tennessee
1993 Distinguished Speaker, National Science Commission, Republic of China
1996 Distinguished Lecturer, Chinese Pharmaceutical Society, Republic of China
1997 Fellow, American Association of Pharmaceutical Scientists
1997 Controlled Release Society Outstanding Pharmaceutical Paper from the 24th International Symposium on Controlled Release of Bioactive Materials
1998 Heward Visting Scientist to the Montreal General Hospital/McGill University
1998 Member, National Gene Vector Laboratories Scientific Review Board
1998-1999 Chairman, Non-viral gene therapy committee, American Society for Gene Therapy
1999 Research Grand Round, Moffitt Cancer Center, Tampa, FL
1999 Plenary Speaker, Japanese Society of Pharmaceutical Sciences, Tokushima, Japan
1999- Member, Medical Biochemistry Study Section, NIH
1999- “Meet The Professor”, American Society of Gene Therapy Annual Meeting
2001 Plenary Speaker, 22nd Annual Eino Nelson Memorial Confernece, Captiva Islnad, FL
2003 Fellow, American Institute for Medical and Biological Engineering
2003-2005 Distinguished Faculty Committee
2004 Alec D Bangham MD FRS Acheivement Award, Liposome Research Days Conference 2004, Hsin-Chu, Taiwan
2006 Elected member of the Advisory Board, American Society of Gene Therapy
2007 Plenary speaker, annual meeting of The Pharmaceutical Society of Taiwan, Taiwan
2008 Plenary speaker, The 6th China-Japan-Korea Foresight Joint Symposium on Gene Delivery and International Symposium on Biomaterials, Sanya, China
2009 Forum speaker, 60th anniversary of Dalian Institute of Chemistry and Physics, Chinese Academy of Sciences, Dalian, China
2009 Plenary speaker, 4th International Conference in Advanced Drug Delivery, Shanghai, China
2009 Honorary Professor, Sichuan University, China
2010 Distinguished speaker, Japan Association for The Advancement of Medical Equipment
2010 Distinguished speaker, Global Center of Excellence, University of Shizuoka, Japan
2010 Distinguished speaker, The Academy of Pharmaceutical Science And Technology, Japan
2010 T. Nagai Postdoc Research Achievement Award, Controlled Release Society. Award was presented to both Dr. Sang Kyoon Kim (postdoc) and Professor Leaf Huang (mentor)
2010 Distinguished speaker, Japan Association for The Advancement of Medical Equipment
2010 Distinguished speaker, Global Center of Excellence, University of Shizuoka, Japan
2010 Distinguished speaker, The Academy of Pharmaceutical Science And Technology, Japan
2010 T. Nagai Postdoc Research Achievement Award, Controlled Release Society. Award was presented to both Dr. Sang Kyoon Kim (postdoc) and Professor Leaf Huang (mentor)
2010 Visiting Chair Professor, Chung-Yuan Christian University, Taiwan
2011 Elected Vice Chair, Gordon Research Conference on “Cancer Nanotechnology”
2011 $100,000 Grant. The North Carolina Biotechnology Center
2012-2015 Elected member, Board of Scientific Advisors, Controlled Release Society
2012 Keynote speaker, Symposium of Advanced Nanomaterials in Biomedicine, Chung Yuan Christian University, Taiwan
2012 Visiting Professor, Fourth Military Medical University, Xi’An, China
2012 Qiushi Chair Professor, Zhejiang University, China (declined)
2012 Changjiang Chair Professor, Zhejiang University, China. Selected by the Ministry of Education, People’s Republic of China (declined)
2013 Senior Visiting Scholar, Fudan University, China
2013 Keynote speaker, Chinese Pharmaceutical Conference, “Lipidic Nanoprecipitates for Drug and Gene Delivery”, Wuhan, China
2013 Distinguished Pharmaceutical Scientist Award, American Society for Pharmaceutical Scientists. This is the highest scientific recognition of AAPS
2014 Qiushi Chair Professor, Zhejiang University, China
2014 Keynote speaker, Cross-Strait Biomaterials and Controlled Drug Release Symposium, Hsinchu, Taiwan
2014 Keynote speaker, NanoDDS2014 conference, Chapel Hill, NC
2015 Keynote speaker, Australian Society of Nanomedicine, Sydney, AU
2015 Visiting professor, ARC Center of Excellence in Convergent Bio-Nano Science and Technology. Lecture tour in three Australian universities 2015
2015 Keynote speaker, International Conference on Applied Materials, Chung Yuan Christian University, Taiwan
2015 $15 million five-year grant. National Cancer Institute for cancer nanotechnology research

 

Memberships in Professional and Scientific Societies

  • Society of Chinese Bio-scientists In America
  • Controlled Release Society
  • American Association of Pharmaceutical Scientists
  • American Society of Gene and Cell Therapy
  • American Association of Colleges of Pharmacy

 

Editorial Activities

1984- 1998 Editorial Board Member Chemistry and Physics of Lipids
1986-1991 Editorial Board Member Journal of Liposome Research
1991-1997 Editor-in-Chief Journal of Liposome Research
1997-present Editor Emeritus Journal of Liposome Research
1992-1999 Editorial Board Member Journal of Drug Targeting
1992-2001 Editorial Board Member BioScience Reports
1993-1999, 2000- Editorial Board Member Gene Therapy
1994-2000 Editorial Advisory Board Bioconjugate Chemistry
1995-present Editorial Board Advanced Drug Delivery Reviews
1999-1999 Associate Editor Gene Therapy
1999-present Editorial Board Member Journal of Gene Medicine
1999-2004 Associate Editor Molecular Therapy
2000-present Editorial Board Member Journal of Controlled Release
2003-present Editorial Board Member Molecular Pharmaceutics
2004-present Editorial Board Member Biological and Pharmaceutical Bulletin
2010-present Editorial Board Member BBA – Biomembranes
2010-present Editorial Board Member Molecular Therapy: Nucleic Acids

 

Current Funding for Huang Lab

Total Direct Cost/y Years Inclusive Grant Number and Title Source
 $217,500 2013-2018

“Hepatic non-viral gene therapy”

1 R01 DK100664, PI: L. Huang

 NIH
 $201,275 2014-2016

“Nanocrystals for the treatment of multidrug resistance in cancer”

1 R01 CA149387, PI: L. Huang

NIH
$1,494,990 2015-2020 

“Nano Approaches to Modulate Host Cell Response for

Cancer Therapy”

1U54CA198999-01, Co-leader: L. Huang & J.E. Tepper

Project 1, PI: L. Huang. $302,668

 NIH

First published in:

Gao, K. and Huang, L. Solid core liposomes with encapsulated colloidal gold particles. Biochim. Biophys. Acta 897:377-383, 1987.Auscl

Thanks to Simon Watkins, PhD, and the Center for Biological Imaging at the University of Pittsburgh for photo preparation and production.simon

Courtesy of Dr. Margret Schmidtgensmiley
Courtesy of Dr. Kazuo Maruyama and Dr. Fan Zhou.ninja

Courtesy of Andrew Satterlee

kicking nanos

HuangStaff2015
Front row: Nasha Qiu,Yi Zhao,Yinghui Wei,Yang Xiong,Yao Lu,Leaf Huang,Lifang Cheng,Ying Xu,Lei Miao,Lina Liu. Back row: Wei Wang,Andrew Satterlee,Kaili Hu,Qi Liu,Yuhua(Al) Wang.

 

Recent Graduate Students

Yuan Zhang

Systemic Delivery of Phosphorylated Nucleoside Analogues and siRNA via LCP Nanoparticles for Cancer Therapy. (Ph.D. 2013) Postdoctoral Fellow, Massachusetts Institute of Technology, Boston.

Yu-Cheng Tseng

LCP Nanoparticles for Tumor and lymph Node Metastasis Imaging. (Ph.D. 2013) Senior Scientist, Taiwan Liposome Company, Taipei, Taiwan.

Yang Liu

Pharmacokinetics and Biodistribution of LCP Nanoparticles. (Ph.D. 2012) Assistant Professor, Chapman University.

Elisabeth Vasievich

Lipid-Based Cancer Vaccines. (Ph.D. 2011) Manager, Roche/Genentech.

Yunching (Becky) Chen

Nanoparticle delivery of siRNA for cancer therapy (Ph.D. 2010) Assistant Professor, National Tsing Hua University, Taiwan.

Jiexin (Jason) Deng

Understanding paclitaxel /pluronic F127 nanocrystals prepared by the stabilization of nanocrystal (SNC) method. (MS, 2009) Graduate Student, University of Florida.

Lisa McEwen (Shollenberger)

Interaction of cationic lipid vaccines with cells of the adaptive immune system (Ph.D. 2009) Research Assistant Professor, University of Georgia.

Amber Frick

PharmD 2009 PhD 2013, University of North Carolina.

Hsin-I (Cindy) Hung

Combined gene therapy of RNA polymerase II driven siRNA and apoptosis inducing factor in a melanoma model. (MS 2008) PhD student, Medical University of South Carolina.

Shyh-Dar (Star) Li

Targeted delivery of siRNA to the tumor (Ph.D. 2008) Associate Professor, School of Pharmacy, University of British Columbia, Vancouver, Canada.

Claire Wei-Hsu Chen

Development of A Simple But Effective Cancer Vaccine Consisting of An Antigen And A Cationic Lipid (Ph.D. 2007) Senior Scientist, Amgen British Columbia, Vancouver, Canada.

Recent Post-Doctoral Fellows

Yuhua “Al” Wang (2010-2015)

 

Zhenghong Xu (2011-2014)

Scientist, Merrimack Pharmaceuticals Inc., Cambridge, MA

Shutao Guo (2011-2014)

Postdoctoral Fellow, Children’s Hospital, Boston, MA

Srinivas Ramishetti (2009 – 2013)

Scientist, Tel Aviv University, Israel

Yunxia Hu (2010-2012)

Senior Investigator, Chinese Academy of Sciences, Yantai, China

Sang Kyoon Kim (2008- 2011)

Senior Scientist, Daegu Gyeongbuk Medical Innovation Foundation, Daegu, Korea

Jun Li (2008- 2011)

Director of Research, Qualiber, Inc., Chapel Hill, NC

Wei-Yun Sheng (2008 – 2011)

Consultant.

Surendar Reddy (2007 – 2008)

Staff scientist, Central Drug Research Institute, Lucknow, India

Ji-Yong Park (2006 – 2008)

Scientist, Food and Drug Administration, Arkansas

Weili Yan (2006 – 2007)

Senior Scientist, Synageva, Inc. Athens, GA

Joyeeta Sen (2005- 2007)

Research Chemist, Hyderabad, India

Recent Visiting Faculty/Scientists and Visiting Students

Nasha Qiu (2014-2015)

PhD student, Zhejiang University, Hangzhou, China

Yang Xiong (2014-2015)

Associate Professor, Zhejiang Traditional Chinese Medical University, Hangzhou, China

Meirong Huo (2014-2015)

Associate Professor, China Pharmaceutical University, Nanjing, China

Ali Badiee (2014-2015)

Assistant Professor, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Yao Lu (2013-2015) PhD student, Huazhong University of Science and Technology, Wuhan, China
Zahra Daman (2014 – 2015) PhD student, Tehran University of Medical Sciences, Tehran, Iran
Yan Zhao (2013-2014) Lecturer, China Medical University, Shenyang, China
Cheng-An James Lin (2013) Assistant Professor, Chung Yuan Christian University, Taiwan
Guimei Lin (2013-2014) Lecturer, Shandong University, Jinan, China
Jing Zhang (2012-2013) Lecturer, Jiangxi Traditional Chinese Medical University, Nanchang, China
Shubiao Zhang (2012-2013) Professor, Dalian Nationality University, Dalian, China
Jing Yao (2012-2013) Associate Professor, Chinese Pharmaceutical University, Nanjing, China
Yun Liu (2012) Graduate student, Peking University, China
Grace Yu (2012) Assistant Investigator, National Health Research Institute, Taiwan
Wei Wang (transferred from Feng Liu group, 2014) Instructor, China Pharmaceutical University, Nanjing, China
Yinghui Wei (transferred from Feng Liu group, 2014) Associate Professor, Zhejiang Traditional Chinese Medical University, Hangzhou, China
Lifang Cheng (transferred from Feng Liu group, 2014) Instructor, Suzhou University, Suzhou, China
Qi Xiang (transferred from Feng Liu group, 2014) Associate Professor, Jinan University, Guangzhou, China
Hongjuan Zhang (transferred from Feng Liu group, 2014) Instructor, Nanjing Medical University, Nanjing, China
Qiang Zhao (transferred from Feng Liu group, 2014) Associate Professor, Sichuan University, Chengdu, China